YKT6 and sarcoma: As shown in Figure 1B, YKT6 was significantly upregulated in Adrenocortical carcinoma (ACC) (P ˂ .05), BLCA, BRCA, CESC, CHOL, COAD, Lymphoid Neoplasm Diffuse Large B-cell (DLBC), ESCA, GBM, HNSC, KICH, KIRP, Brain Lower Grade Glioma (LGG), LIHC, LUAD, LUSC, Ovarian serous cystadenocarcinoma (OV), Pancreatic adenocarcinoma (PAAD), PRAD, Rectum adenocarcinoma (READ), Sarcoma (SARC), Skin Cutaneous Melanoma (SKCM), STAD, Testicular Germ Cell Tumors (TGCT), Thymoma (THYM), UCEC and Uterine Carcinosarcoma (UCS) (P ˂ .001).